Compared to the E2 group (50 μg/kg/day, six times a week), which increased TC, TG levels and expression of tumor markers, the ECH treatment groups displays improved lipid parameters and reduced tumor markers CA-125 and CEA expression. The gene discussed is CEACAM5; the disease is neoplasm.